Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 16.66
- Piotroski Score 3.00
- Grade Buy
- Symbol (ATOS)
- Company Atossa Therapeutics, Inc.
- Price $1.51
- Changes Percentage (8.29%)
- Change $0.12
- Day Low $1.40
- Day High $1.51
- Year High $2.31
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/11/2024
- Fiscal Year End N/A
- Average Stock Price Target $5.00
- High Stock Price Target $5.00
- Low Stock Price Target $5.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.24
- Trailing P/E Ratio -5.21
- Forward P/E Ratio -5.21
- P/E Growth -5.21
- Net Income $-30,094,000
Income Statement
Quarterly
Annual
Latest News of ATOS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
ATOSS Software's (ETR:AOF) five-year total shareholder returns outpace the underlying earnings growth
ATOSS Software SE shares have dropped 15% this week, but long-term returns show a 272% increase over five years, indicating strong business performance. Market sentiment affects share prices, but EPS ...
By Yahoo! Finance | 3 weeks ago -
San Francisco Giants takeaways: The impact of the Luciano, Matos and Eldridge promotions
The Giants made significant roster moves in September, promoting top prospects and making room for young talents. Focus is on Luciano's defensive skills and McCray's playing time. Eldridge's rapid ris...
By The New York Times | 3 weeks ago -
France's Atos cuts financial targets but says restructuring still on track
Atos, a French IT firm, expects reduced cash flow in the coming years due to a challenging business environment but reassures that its financial restructuring plan will remain intact. The company aims...
By Yahoo! Finance | 4 weeks ago